Outcome measures of phase III anticancer drug trials in China.

Author: Lanwei GUO ¹ ; Huiyao HUANG ² ; Yue YU ² ; Jun WANG ³ ; Le WANG ⁴ ; Shuhang WANG ² ; Dawei WU ² ; Yuan FANG ² ; Ning JIANG ² ; Shaokai ZHANG ¹ ; Yu TANG ² ; Ning LI ²
Author Information

1. Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
2. Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
3. National Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
4. Department of Cancer Prevention, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, China.
Publication Type:Journal Article
MeSH: Humans; Antineoplastic Agents/therapeutic use*; Neoplasms/drug therapy*; Outcome Assessment, Health Care; China
From: Chinese Medical Journal 2023;136(8):992-994
CountryChina
Language:English